Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement

Nov

11

Today In Oncology

KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC

FDA Approves Pimicotinib for Symptomatic TGCT

HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC

Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer

Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies

Advertisement

© 2026 HSP News Service, L.L.C.